For research use only. Not Intended for Therapeutic Use!
|IC50:||3.4/12/16/16/32 nM(PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR) |
|We would like to match the lowest price on market if possible.|
GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively.
IC50 value: 3.4/12/16/16/32 nM(PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR) 
Target: pan-PI3K/mTOR inhibitor
GNE-493 has good pharmacokinetic (PK) parameters, GNE-493 is highly selective, demonstrate knock down of pathway markers in vivo, and are efficacious in xenograft models where the PI3K pathway is deregulated. GNE-493 was compared in a PI3KR mutated MCF7.1 xenograft model and were found to have equivalent efficacy when normalized for exposure.
. Sutherlin DP, et al. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem. 2010 Feb 11;53(3):1086-97.